Nanocrystalline Gold to Treat Remyelination Failure in Chronic Optic Neuropathy In Multiple Sclerosis (VISIONARY-MS)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03536559 |
|
Recruitment Status :
Terminated
(COVID-19 related enrollment challenges.)
First Posted : May 24, 2018
Last Update Posted : August 12, 2022
|
Sponsor:
Clene Nanomedicine
Collaborator:
Clene Australia Pty Ltd
Information provided by (Responsible Party):
Clene Nanomedicine
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Terminated |
|---|---|
| Actual Primary Completion Date : | April 27, 2022 |
| Actual Study Completion Date : | July 12, 2022 |